<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04680377</url>
  </required_header>
  <id_info>
    <org_study_id>IIT-2019-AZmicrobiome</org_study_id>
    <nct_id>NCT04680377</nct_id>
  </id_info>
  <brief_title>Using Microbiome to Predict Durvalumab Toxicity in Post- Concurrent Chemoradiation Therapy (CCRT) NSCLC Patients</brief_title>
  <acronym>Microdurva</acronym>
  <official_title>Using Microbiome to Predict Durvalumab Toxicity in Post-CCRT NSCLC Patients (Microdurva)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jun Zhang, MD, PhD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Rhode Island Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Kansas Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase IV study is hoping to determine if examining the microbiome in non-small cell lung&#xD;
      cancer participants who will receive durvalumab can predict treatment toxicity.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 12, 2020</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Grade 3 or higher adverse events (AE's)</measure>
    <time_frame>Up to 18 months</time_frame>
    <description>CTCAE 5.0</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Longitudinal changes in Microbiome</measure>
    <time_frame>Up to 18 months from study start</time_frame>
    <description>Metagenomic sequencing and taxonomic analysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Longitudinal changes in bacterial metabolic pathway</measure>
    <time_frame>Up to 18 months from study start</time_frame>
    <description>Metagenomic sequencing and Kyoto Encyclopedia of Genes and Genomes (KEGG) mapping</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time-to-treatment withheld due to AEs</measure>
    <time_frame>Up to 18 months from study start</time_frame>
    <description>Time measured by days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to immune-mediated AEs requiring systemic intervention</measure>
    <time_frame>Up to 18 months from study start</time_frame>
    <description>Time measured by days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>Up to 36 months from study start</time_frame>
    <description>Time measured by months</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">44</enrollment>
  <condition>NSCLC, Stage III</condition>
  <condition>Locally Advanced Lung Carcinoma</condition>
  <arm_group>
    <arm_group_label>Participants receiving standard of care durvalumab</arm_group_label>
    <description>Prior to receiving treatment participants will have samples taken from three different sources to test the microbiome bacteria to determine if it will help predict toxicity to the treatment</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      nasal and buccal swabs, and stool&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Participants must have histologically- or cytologically-documented NSCLC who present with&#xD;
        locally advanced, unresectable (Stage III) disease.&#xD;
&#xD;
        Participants must have not progressed following definitive, platinum-based, concurrent&#xD;
        chemoradiation therapy.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Ability of participant OR Legally Authorized Representative (LAR) to understand this&#xD;
             study, and participant or LAR willingness to sign a written informed consent&#xD;
&#xD;
          -  Participant is willing and able to comply with the protocol for the duration of the&#xD;
             study including undergoing treatment and scheduled visits and examinations including&#xD;
             follow up&#xD;
&#xD;
          -  Life expectancy ≥12 weeks&#xD;
&#xD;
          -  Males and females age ≥ 18 years&#xD;
&#xD;
          -  Allowable type and amount of prior therapy:&#xD;
&#xD;
        Participants must have received two or more cycles of platinum-based chemotherapy&#xD;
        (containing etoposide, vinblastine, vinorelbine, a taxane [paclitaxel or docetaxel], or&#xD;
        pemetrexed) concurrently with definitive radiation therapy (54-66 Gy)&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) Performance Status = 0 or 1&#xD;
&#xD;
          -  Body weight &gt;30 kg (66.14 lbs)&#xD;
&#xD;
          -  Participants must have histologically- or cytologically-documented NSCLC who present&#xD;
             with locally advanced, unresectable (Stage III) disease&#xD;
&#xD;
          -  Participants must have not progressed following definitive, platinum-based, concurrent&#xD;
             chemoradiation therapy&#xD;
&#xD;
          -  Adequate organ function based on laboratory results&#xD;
&#xD;
          -  Women of child-bearing potential and men with partners of child-bearing potential must&#xD;
             agree to practice sexual abstinence, or to use an acceptable form of contraception for&#xD;
             the duration of study participation, and for the time specified following completion&#xD;
             of therapy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Concurrent enrollment in another clinical study, unless it is an observational&#xD;
             (non-interventional) clinical study or if the participant is in the follow-up period&#xD;
             of an interventional study&#xD;
&#xD;
          -  Participation in another clinical study with an investigational product during the&#xD;
             last 4 weeks prior to enrollment on this study&#xD;
&#xD;
          -  Prior randomization or treatment in a previous durvalumab clinical study regardless of&#xD;
             treatment arm assignment&#xD;
&#xD;
          -  Mixed small cell and non-small cell lung cancer histology&#xD;
&#xD;
          -  Participants who receive sequential chemoradiation therapy for locally advanced NSCLC&#xD;
&#xD;
          -  Participants with locally advanced NSCLC who have progressed whilst definitive&#xD;
             platinum based, concurrent chemoradiation therapy&#xD;
&#xD;
          -  Receipt of any investigational drug within 4 weeks prior to the first dose of&#xD;
             durvalumab; and in the case of monoclonal antibodies (not immunotherapy) 6 weeks prior&#xD;
             to the first dose of durvalumab&#xD;
&#xD;
          -  Participants who have received prior anti-programmed death (PD)-1, anti- programmed&#xD;
             death ligand (PD-L)1 or anti- cytotoxic T-lymphocyte-associated protein (CTLA)-4&#xD;
&#xD;
          -  Participants who have received prior immunotherapy&#xD;
&#xD;
          -  Receipt of live attenuated vaccine within 30 days prior to the first dose of&#xD;
             investigational product (IP). Note: Participants, if enrolled, should not receive live&#xD;
             vaccine whilst receiving durvalumab and up to 30 days after the last dose of IP&#xD;
&#xD;
          -  Current or prior use of immunosuppressive medication within 14 days before the first&#xD;
             dose of durvalumab&#xD;
&#xD;
          -  Any unresolved toxicity CTCAE ≥ Grade 2 from the prior chemoradiation / anticancer&#xD;
             therapy with the exception of alopecia, vitiligo, and the laboratory values defined in&#xD;
             the inclusion criteria&#xD;
&#xD;
          -  Any grade pneumonitis from prior chemoradiation therapy&#xD;
&#xD;
          -  Active infection&#xD;
&#xD;
          -  Recent major surgery within 28 days prior to the first dose of study therapy&#xD;
&#xD;
          -  Active or prior documented autoimmune or inflammatory disorders&#xD;
&#xD;
          -  History of primary immunodeficiency&#xD;
&#xD;
          -  History of another primary malignancy&#xD;
&#xD;
          -  History of allogenic organ transplantation/organ transplant that requires therapeutic&#xD;
             immunosuppression&#xD;
&#xD;
          -  History of leptomeningeal carcinomatosis&#xD;
&#xD;
          -  Participants with active ventricular arrhythmia requiring medication&#xD;
&#xD;
          -  Uncontrolled intercurrent illness&#xD;
&#xD;
          -  Participants who have progressed following definitive, platinum-based, concurrent&#xD;
             chemoradiation therapy&#xD;
&#xD;
          -  Known allergy or hypersensitivity to durvalumab or any of durvalumab's excipients&#xD;
&#xD;
          -  Psychiatric illness/social situations that would limit compliance with study&#xD;
             requirements or compromise the ability of the patient to give written informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jun Zhang, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Kansas Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>KUCC Navigation</last_name>
    <phone>9135883671</phone>
    <email>kucc_Navigation@kumc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>The University of Kansas Cancer Center, Westwood Campus</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Nurse Navigator</last_name>
      <phone>913-945-7552</phone>
      <email>ctnursenav@kumc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rhode Island Hospital, Brown University</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hina Khan, MD</last_name>
      <email>hina.khan@lifespan.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Swami U, Zakharia Y, Zhang J. Understanding Microbiome Effect on Immune Checkpoint Inhibition in Lung Cancer: Placing the Puzzle Pieces Together. J Immunother. 2018 Oct;41(8):359-360. doi: 10.1097/CJI.0000000000000232. Review.</citation>
    <PMID>29781826</PMID>
  </reference>
  <reference>
    <citation>Strouse C, Mangalam A, Zhang J. Bugs in the system: bringing the human microbiome to bear in cancer immunotherapy. Gut Microbes. 2019;10(2):109-112. doi: 10.1080/19490976.2018.1511665. Epub 2018 Sep 5.</citation>
    <PMID>30183502</PMID>
  </reference>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>December 17, 2020</study_first_submitted>
  <study_first_submitted_qc>December 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 23, 2020</study_first_posted>
  <last_update_submitted>April 4, 2021</last_update_submitted>
  <last_update_submitted_qc>April 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Kansas Medical Center</investigator_affiliation>
    <investigator_full_name>Jun Zhang, MD, PhD</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

